肝癌栓塞化疗后免疫及中药治疗的临床观察

目的 :探讨肝癌患者栓塞化疗后 ,免疫及中药治疗对其生存时间与机体免疫功能状态的影响。方法 :1 0 8例肝癌患者随机分为甲、乙、丙组。进行单纯肝动脉栓塞化疗及栓塞化疗后分别给予免疫增强剂及中药治疗。结果 :近期有效率分别为 61 1 %、83 3 %、80 6%。 3年生存率分别为 2 8 6%、3 9 1 %、47 4%。中位生存时间分别为 1 1、1 7、1 5个月。治疗后免疫功能检查 ,单纯栓塞化疗患者机体免疫力低下 ,而用免疫增强剂与中药治疗者则机体免疫能力增强。结论 :患者生存时间与机体免疫功能强弱有关 ,免疫力增强 ,则生存时间相对延长。

英文摘要:

Objective: To probe the relationship between survival period and immune function of hepatic carcinoma patients after embolism chemotherapy. Methods: One hundred and eight patients of hepatocarcinoma were randomly divided into three groups. Group A was given simple embolism chemotherapy (ECT), immunotherapy and Chinese herbal medicine were given to Group B and C respectively aftre ECT. Results: The short term effective rate of Group A, B and C was 61.1% ,83 3% and 80 6% respectively, three year survival rate 28 6%, 39 1% and 47 3%, median length of survival 11,17 and 15 months respectively. The difference in terms of these indices were significant. Observation on immune function after treatment showed that patients received ECT alone had a lower immunity than those supplemented with immunotherapy or Chinese herbal medicine. Conclusions: Period of survival of hepatocarcinoma patients is related with their immune function. Patients with better immunity could enjoy a relatively extended period of survival.

关闭